Ann: 50% recruitment reached for Phase II prostate cancer trial, page-26

As i understand it the Point tech is offering Lantheus a theropy based on 177LU. Along with their existing Diagnostic based on 68GA they have the oportunity to have both Diagnostic and Theropy supply.
The same issues will be issues with logistics and supply. These products are very difficult to supply, move around and they are expensive. They are hard to work with generally, and not great for the consumer with higher toxicity problems.
Clarity can deliver to any post code in the USA, and is not restricted to hospital radiopharmacies. It is admistered by a technolgist, so it reduces the skilled labour demand and infrastructure requirements.
When Clarity release their perfect pariring of Cu64 and CU67 it will also be cheaper. Much cheaper.
Logistically Clarity is a dream compared to current.
Claritys product is highlyprecise and highly accurate targeting of theroputics., unlike the alternatives.
There is potential for less side effects in off target organs using Clarity.
Clarity still have a good year of work to get to phase three of their Cu67 trials (theropy) to efficacy and safty.
It may also be interesting for Lanthius, AZ,Curium, and others to have Beta technology in their portfolio of products. Not just Alpha.

Hope that helps.